Cormedix affirms FY2026 sales guidance at $325M–$345M
Cormedix (NASDAQ: CRMD) affirms FY2026 sales guidance of $325.000M–$345.000M, compared with a $334.089M estimate, with the range unchanged from the prior outlook.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.